Skip to search formSkip to main contentSkip to account menu

dexlansoprazole

Known as: Lansoprazole, R Isomer, R-Lansoprazole, Dexlansoprazole [Chemical/Ingredient] 
The R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. As a weak base… 
National Institutes of Health

Related topics

Related topics

14 relations

Broader (2)

Anti-Ulcer AgentProton Pump Inhibitors

Narrower (3)

DexilantTAK 390MRTAK-390
In Bloodagonistsanalogs & derivativesantagonists & inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Dexlansoprazole – a new-generation proton pump inhibitor
Dexlansoprazole modified release (MR) is an R-enantiomer of lansoprazole and a new-generation proton pump inhibitor exhibiting… 
Review
2013
Review
2013
Exploiting the Power of Stereochemistry in Drugs: An Overview of Racemic and Enantiopure Drugs
Abstract: Stereochemistry is one of the essential dimensions in pharmacology as it dictates how enantiomers interact with… 
Highly Cited
2011
Highly Cited
2011
The Effect of Dexlansoprazole MR on Nocturnal Heartburn and GERD-Related Sleep Disturbances in Patients With Symptomatic GERD
OBJECTIVES:Nocturnal heartburn and related sleep disturbances are common among patients with gastroesophageal reflux disease… 
Review
2011
Review
2011
Dexlansoprazole MR – A review
Abstract Dexlansoprazole MR is the R-enantiomer of lansoprazole that is delivered by a novel system, the dual delayed release… 
2011
2011
Withdrawing PPI Therapy After Healing Esophagitis Does Not Worsen Symptoms or Cause Persistent Hypergastrinemia: Analysis of Dexlansoprazole MR Clinical Trial Data
OBJECTIVES:Withdrawal of proton pump inhibitors (PPIs) may induce symptoms in healthy volunteers, suggesting that discontinuing… 
2010
2010
The effect of time‐of‐day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor
Aliment Pharmacol Ther 31, 1001–1011 
Review
2009
Review
2009
Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy
Background  Proton pump inhibitors (PPIs) provide the most effective pharmacotherapy for treating acid‐related disorders. However… 
2009
2009
Effects of Dexlansoprazole MR, a Novel Dual Delayed Release Formulation of a Proton Pump Inhibitor, on Plasma Gastrin Levels in Healthy Subjects
Dexlansoprazole MR is a modified release formulation of a proton pump inhibitor being developed for the treatment of acid‐related… 
2009
2009
Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials*
ABSTRACT Background: Dexlansoprazole MR is a novel Dual Delayed Release formulation of dexlansoprazole, an enantiomer of… 
2005
2005
Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro
The stereoselectivity of the inhibitory interaction potential of lansoprazole and omeprazole isomers on six human cytochrome P450… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)